| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Achieving confidence in mechanism for drug discovery and development
|
Pitluk, Zach
|
|
2007
|
|
21-22 |
p. 924-930
7 p.
|
artikel
|
| 2 |
A minimalist fragment approach for the design of natural-product-like synthetic scaffolds
|
Genis, Dmitry
|
|
2012
|
|
21-22 |
p. 1170-1174
5 p.
|
artikel
|
| 3 |
Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market
|
Hashitera, Yukiko
|
|
2013
|
|
21-22 |
p. 1109-1116
8 p.
|
artikel
|
| 4 |
A second vaccine revolution for the new epidemics of the 21st century
|
Dyer, Mark R.
|
|
2006
|
|
21-22 |
p. 1028-1033
6 p.
|
artikel
|
| 5 |
Big dreams, small island—the prospects of Taiwan's biotech economy
|
Agoramoorthy, Govindasamy
|
|
2007
|
|
21-22 |
p. 894-897
4 p.
|
artikel
|
| 6 |
Brain drug targeting: a computational approach for overcoming blood–brain barrier
|
Mehdipour, Ahmad Reza
|
|
2009
|
|
21-22 |
p. 1030-1036
7 p.
|
artikel
|
| 7 |
Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery
|
Pepper, Dominique J.
|
|
2007
|
|
21-22 |
p. 980-989
10 p.
|
artikel
|
| 8 |
Contents
|
|
|
2009
|
|
21-22 |
p. i-
1 p.
|
artikel
|
| 9 |
Contents
|
|
|
2009
|
|
21-22 |
p. iii-
1 p.
|
artikel
|
| 10 |
Contents
|
|
|
2010
|
|
21-22 |
p. iii-
1 p.
|
artikel
|
| 11 |
Contents
|
|
|
2007
|
|
21-22 |
p. i-
1 p.
|
artikel
|
| 12 |
Contents
|
|
|
2010
|
|
21-22 |
p. i-
1 p.
|
artikel
|
| 13 |
Contents
|
|
|
2013
|
|
21-22 |
p. iii-
1 p.
|
artikel
|
| 14 |
Contents
|
|
|
2013
|
|
21-22 |
p. i-
1 p.
|
artikel
|
| 15 |
Contents
|
|
|
2012
|
|
21-22 |
p. iii-
1 p.
|
artikel
|
| 16 |
Contents
|
|
|
2012
|
|
21-22 |
p. i-
1 p.
|
artikel
|
| 17 |
Contents page 2
|
|
|
2008
|
|
21-22 |
p. iii-
1 p.
|
artikel
|
| 18 |
Contents page 1
|
|
|
2008
|
|
21-22 |
p. i-
1 p.
|
artikel
|
| 19 |
Contents page 2
|
|
|
2011
|
|
21-22 |
p. iii-
1 p.
|
artikel
|
| 20 |
Contents page 1
|
|
|
2011
|
|
21-22 |
p. i-
1 p.
|
artikel
|
| 21 |
Cost-effectiveness analysis: should it be required for drug registration and beyond?
|
Arnold, Renée J. Goldberg
|
|
2007
|
|
21-22 |
p. 960-965
6 p.
|
artikel
|
| 22 |
Data analysis of alternative splicing microarrays
|
Cuperlovic-Culf, Miroslava
|
|
2006
|
|
21-22 |
p. 983-990
8 p.
|
artikel
|
| 23 |
Developing a paradigm of drug innovation: an evaluation algorithm
|
Caprino, Luciano
|
|
2006
|
|
21-22 |
p. 999-1006
8 p.
|
artikel
|
| 24 |
Diagnostic challenges for multiplexed protein microarrays
|
Master, Stephen R.
|
|
2006
|
|
21-22 |
p. 1007-1011
5 p.
|
artikel
|
| 25 |
Diary
|
|
|
2006
|
|
21-22 |
p. 1042-
1 p.
|
artikel
|
| 26 |
Dihydropyridines: evaluation of their current and future pharmacological applications
|
Edraki, Najmeh
|
|
2009
|
|
21-22 |
p. 1058-1066
9 p.
|
artikel
|
| 27 |
DNA fragmentation based combinatorial approaches to soluble protein expression
|
Savva, Renos
|
|
2007
|
|
21-22 |
p. 939-947
9 p.
|
artikel
|
| 28 |
DNA fragmentation-based combinatorial approaches to soluble protein expression
|
Prodromou, Chrisostomos
|
|
2007
|
|
21-22 |
p. 931-938
8 p.
|
artikel
|
| 29 |
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug
|
Fiume, Luigi
|
|
2008
|
|
21-22 |
p. 1002-1009
8 p.
|
artikel
|
| 30 |
Drug dealers: $20 trillion of in-licensing payments
|
Frei, Patrik
|
|
2013
|
|
21-22 |
p. 1027-1029
3 p.
|
artikel
|
| 31 |
Drug discovery: are productivity metrics inhibiting motivation and creativity?
|
Ullman, Fredrik
|
|
2008
|
|
21-22 |
p. 997-1001
5 p.
|
artikel
|
| 32 |
Drug discovery dilemma and Cura Quartet collaboration
|
Shah, Salim
|
|
2009
|
|
21-22 |
p. 1006-1010
5 p.
|
artikel
|
| 33 |
Drug discovery: past, present and future
|
Malik, Nafees N.
|
|
2008
|
|
21-22 |
p. 909-912
4 p.
|
artikel
|
| 34 |
Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design
|
Vaidehi, Nagarajan
|
|
2010
|
|
21-22 |
p. 951-957
7 p.
|
artikel
|
| 35 |
Editorial Board
|
|
|
2007
|
|
21-22 |
p. iii-
1 p.
|
artikel
|
| 36 |
Empowering industrial research with shared biomedical vocabularies
|
Harland, Lee
|
|
2011
|
|
21-22 |
p. 940-947
8 p.
|
artikel
|
| 37 |
Engineering in vitro microenvironments for cell based therapies and drug discovery
|
Cigognini, Daniela
|
|
2013
|
|
21-22 |
p. 1099-1108
10 p.
|
artikel
|
| 38 |
Erratum: Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy
|
|
|
2007
|
|
21-22 |
p. 990-
1 p.
|
artikel
|
| 39 |
Evolution of the physicochemical properties of marketed drugs: can history foretell the future?
|
Faller, Bernard
|
|
2011
|
|
21-22 |
p. 976-984
9 p.
|
artikel
|
| 40 |
Failure is an option: learning from unsuccessful proof-of-concept trials
|
Schäfer, Stefan
|
|
2008
|
|
21-22 |
p. 913-916
4 p.
|
artikel
|
| 41 |
Finding a better path to drug selectivity
|
Kawasaki, Yuko
|
|
2011
|
|
21-22 |
p. 985-990
6 p.
|
artikel
|
| 42 |
Flavonoids and genomic instability induced by ionizing radiation
|
Hosseinimehr, Seyed Jalal
|
|
2010
|
|
21-22 |
p. 907-918
12 p.
|
artikel
|
| 43 |
Genetically manipulated adult stem cells for wound healing
|
Peng, Li-Hua
|
|
2011
|
|
21-22 |
p. 957-966
10 p.
|
artikel
|
| 44 |
Global analytical strategy to measure drug–plasma protein interactions: from high-throughput to in-depth analysis
|
Vuignier, Karine
|
|
2013
|
|
21-22 |
p. 1030-1034
5 p.
|
artikel
|
| 45 |
Groundbreaking gold(III) anticancer agents
|
Aldinucci, Donatella
|
|
2009
|
|
21-22 |
p. 1075-1076
2 p.
|
artikel
|
| 46 |
Harnessing opportunities in non-animal asthma research for a 21st-century science
|
Buckland, Gemma L.
|
|
2011
|
|
21-22 |
p. 914-927
14 p.
|
artikel
|
| 47 |
HIV vaccine: hopes and hurdles
|
Chhatbar, Chintan
|
|
2011
|
|
21-22 |
p. 948-956
9 p.
|
artikel
|
| 48 |
Image-guided drug delivery to the brain using nanotechnology
|
Ding, Hong
|
|
2013
|
|
21-22 |
p. 1074-1080
7 p.
|
artikel
|
| 49 |
Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery
|
Hu, Shen
|
|
2007
|
|
21-22 |
p. 911-916
6 p.
|
artikel
|
| 50 |
In search of sustainability: process R&D in light of current pharmaceutical industry challenges
|
Federsel, Hans-Jürgen
|
|
2006
|
|
21-22 |
p. 966-974
9 p.
|
artikel
|
| 51 |
Kinase packing defects as drug targets
|
Crespo, Alejandro
|
|
2007
|
|
21-22 |
p. 917-923
7 p.
|
artikel
|
| 52 |
Kinetic efficiency: the missing metric for enhancing compound quality?
|
Holdgate, Geoffrey A.
|
|
2011
|
|
21-22 |
p. 910-913
4 p.
|
artikel
|
| 53 |
Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design
|
Hosseinimehr, Seyed Jalal
|
|
2012
|
|
21-22 |
p. 1224-1232
9 p.
|
artikel
|
| 54 |
Maintaining the silence: reflections on long-term RNAi
|
Raemdonck, Koen
|
|
2008
|
|
21-22 |
p. 917-931
15 p.
|
artikel
|
| 55 |
Marine natural products as sources of novel scaffolds: achievement and concern
|
Kong, De-Xin
|
|
2010
|
|
21-22 |
p. 884-886
3 p.
|
artikel
|
| 56 |
MCH-R1 antagonists: what is keeping most research programs away from the clinic?
|
Méndez-Andino, José L.
|
|
2007
|
|
21-22 |
p. 972-979
8 p.
|
artikel
|
| 57 |
MEMS technology for nanobio research
|
Collard, Dominique
|
|
2008
|
|
21-22 |
p. 989-996
8 p.
|
artikel
|
| 58 |
Mobile apps for chemistry in the world of drug discovery
|
Williams, Antony J.
|
|
2011
|
|
21-22 |
p. 928-939
12 p.
|
artikel
|
| 59 |
Model fluids representing aqueous in-vitro diagnostic reagents for the development of dispensing systems
|
Losleben, Nadine
|
|
2013
|
|
21-22 |
p. 1035-1042
8 p.
|
artikel
|
| 60 |
Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary
|
Jarzabek, Monika A.
|
|
2013
|
|
21-22 |
p. 1052-1066
15 p.
|
artikel
|
| 61 |
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery
|
Wood, Jill
|
|
2013
|
|
21-22 |
p. 1043-1051
9 p.
|
artikel
|
| 62 |
New aromatase inhibitors with potential in breast cancer treatment
|
Westwell, Andrew D.
|
|
2006
|
|
21-22 |
p. 1041-
1 p.
|
artikel
|
| 63 |
New challenges for pharmaceutical formulations and drug delivery systems characterization using isothermal titration calorimetry
|
Bouchemal, Kawthar
|
|
2008
|
|
21-22 |
p. 960-972
13 p.
|
artikel
|
| 64 |
New therapeutics for the prevention and reduction of scarring
|
Occleston, Nick L.
|
|
2008
|
|
21-22 |
p. 973-981
9 p.
|
artikel
|
| 65 |
NMR methods in fragment screening: theory and a comparison with other biophysical techniques
|
Dalvit, Claudio
|
|
2009
|
|
21-22 |
p. 1051-1057
7 p.
|
artikel
|
| 66 |
Novel anti-cholinergics in COPD
|
Prakash, A.
|
|
2013
|
|
21-22 |
p. 1117-1126
10 p.
|
artikel
|
| 67 |
Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation
|
Bansal, Tripta
|
|
2009
|
|
21-22 |
p. 1067-1074
8 p.
|
artikel
|
| 68 |
Nucleic acid sample preparation for in vitro molecular diagnosis: from conventional techniques to biotechnology
|
Rahman, Md Mahbubor
|
|
2012
|
|
21-22 |
p. 1199-1207
9 p.
|
artikel
|
| 69 |
One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade
|
Villoutreix, Bruno O.
|
|
2013
|
|
21-22 |
p. 1081-1089
9 p.
|
artikel
|
| 70 |
Open Innovation: share or die…
|
Talaga, Patrice
|
|
2009
|
|
21-22 |
p. 1003-1005
3 p.
|
artikel
|
| 71 |
Open PHACTS: semantic interoperability for drug discovery
|
Williams, Antony J.
|
|
2012
|
|
21-22 |
p. 1188-1198
11 p.
|
artikel
|
| 72 |
Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases
|
Mei, Hongkang
|
|
2012
|
|
21-22 |
p. 1208-1216
9 p.
|
artikel
|
| 73 |
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
|
Desjarlais, John R.
|
|
2007
|
|
21-22 |
p. 898-910
13 p.
|
artikel
|
| 74 |
Patches for improving gastrointestinal absorption: an overview
|
Teutonico, Donato
|
|
2011
|
|
21-22 |
p. 991-997
7 p.
|
artikel
|
| 75 |
Personalized medicine: potential impact on the biopharmaceutical industry
|
Malik, Nafees N.
|
|
2010
|
|
21-22 |
p. 881-883
3 p.
|
artikel
|
| 76 |
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET
|
Slobbe, Paul
|
|
2012
|
|
21-22 |
p. 1175-1187
13 p.
|
artikel
|
| 77 |
PET tracers for the peripheral benzodiazepine receptor and uses thereof
|
Schweitzer, Pernilla J.
|
|
2010
|
|
21-22 |
p. 933-942
10 p.
|
artikel
|
| 78 |
Phenotypic screens as a renewed approach for drug discovery
|
Zheng, Wei
|
|
2013
|
|
21-22 |
p. 1067-1073
7 p.
|
artikel
|
| 79 |
Playing hard balls with RNA: fully automated ab initio RNA folding by discrete molecular dynamics
|
Demidov, Vadim V.
|
|
2008
|
|
21-22 |
p. 1010-1011
2 p.
|
artikel
|
| 80 |
Polymer gene delivery: overcoming the obstacles
|
Aied, Ahmed
|
|
2013
|
|
21-22 |
p. 1090-1098
9 p.
|
artikel
|
| 81 |
Principles for 3D/4D QSAR classification of drugs
|
Potemkin, Vladimir
|
|
2008
|
|
21-22 |
p. 952-959
8 p.
|
artikel
|
| 82 |
Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare
|
Wellenreuther, Ruth
|
|
2012
|
|
21-22 |
p. 1242-1248
7 p.
|
artikel
|
| 83 |
Rational and efficient geometric definition of pharmacophores is essential for the patent process
|
Guérin, Georges-Alexandre
|
|
2006
|
|
21-22 |
p. 991-998
8 p.
|
artikel
|
| 84 |
Recent approaches for the treatment of periodontitis
|
Jain, Nilu
|
|
2008
|
|
21-22 |
p. 932-943
12 p.
|
artikel
|
| 85 |
Revealing promiscuous drug–target interactions by chemical proteomics
|
Bantscheff, Marcus
|
|
2009
|
|
21-22 |
p. 1021-1029
9 p.
|
artikel
|
| 86 |
Selectins – potential pharmacological targets?
|
Kneuer, Carsten
|
|
2006
|
|
21-22 |
p. 1034-1040
7 p.
|
artikel
|
| 87 |
Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability
|
Kohli, Kanchan
|
|
2010
|
|
21-22 |
p. 958-965
8 p.
|
artikel
|
| 88 |
Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning
|
Henriksen, Kim
|
|
2011
|
|
21-22 |
p. 967-975
9 p.
|
artikel
|
| 89 |
Solubility: it's not just for physical chemists
|
Bhattachar, Shobha N.
|
|
2006
|
|
21-22 |
p. 1012-1018
7 p.
|
artikel
|
| 90 |
Syntheses of novel compounds targeting metalloprotease and antibacterial targets
|
Edwards, Paul
|
|
2007
|
|
21-22 |
p. 991-992
2 p.
|
artikel
|
| 91 |
Targeting mutant huntingtin for the development of disease-modifying therapy
|
Appl, Thomas
|
|
2012
|
|
21-22 |
p. 1217-1223
7 p.
|
artikel
|
| 92 |
The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow
|
Pors, Klaus
|
|
2009
|
|
21-22 |
p. 1045-1050
6 p.
|
artikel
|
| 93 |
The design, structures and therapeutic potential of protein epitope mimetics
|
Robinson, John A.
|
|
2008
|
|
21-22 |
p. 944-951
8 p.
|
artikel
|
| 94 |
The economics of priority review vouchers
|
Dimitri, Nicola
|
|
2010
|
|
21-22 |
p. 887-891
5 p.
|
artikel
|
| 95 |
The heterozygous Sod2 +/− mouse: modeling the mitochondrial role in drug toxicity
|
Boelsterli, Urs A.
|
|
2008
|
|
21-22 |
p. 982-988
7 p.
|
artikel
|
| 96 |
The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?
|
Ritchie, Timothy J.
|
|
2009
|
|
21-22 |
p. 1011-1020
10 p.
|
artikel
|
| 97 |
The impact of pharmacogenetics on the development and use of antipsychotic drugs
|
Reynolds, Gavin P.
|
|
2007
|
|
21-22 |
p. 953-959
7 p.
|
artikel
|
| 98 |
The long and difficult road to the diagnostic market: protein microarrays
|
Joos, Thomas O.
|
|
2006
|
|
21-22 |
p. 959-961
3 p.
|
artikel
|
| 99 |
The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease
|
’t Hart, Bert A.
|
|
2012
|
|
21-22 |
p. 1160-1165
6 p.
|
artikel
|
| 100 |
The promise of South African biotech
|
Akermann, Britt
|
|
2006
|
|
21-22 |
p. 962-965
4 p.
|
artikel
|
| 101 |
Therapeutic potential of antifungal plant and insect defensins
|
Thevissen, Karin
|
|
2007
|
|
21-22 |
p. 966-971
6 p.
|
artikel
|
| 102 |
Thermodynamics guided lead discovery and optimization
|
Ferenczy, György G.
|
|
2010
|
|
21-22 |
p. 919-932
14 p.
|
artikel
|
| 103 |
The role and impact of quantitative discovery pathology
|
Potts, Steven J.
|
|
2010
|
|
21-22 |
p. 943-950
8 p.
|
artikel
|
| 104 |
The role of Ca2+ in ultrasound-elicited bioeffects: progress, perspectives and prospects
|
Hassan, Mariame A.
|
|
2010
|
|
21-22 |
p. 892-906
15 p.
|
artikel
|
| 105 |
Topography-biased compound library design: the shape of things to come?
|
Akritopoulou-Zanze, Irini
|
|
2007
|
|
21-22 |
p. 948-952
5 p.
|
artikel
|
| 106 |
Towards the discovery of drug-like RNA ligands?
|
Foloppe, Nicolas
|
|
2006
|
|
21-22 |
p. 1019-1027
9 p.
|
artikel
|
| 107 |
Tuberculosis and AIDS – a devilish liaison
|
Kaufmann, Stefan H.E.
|
|
2007
|
|
21-22 |
p. 891-893
3 p.
|
artikel
|
| 108 |
Ultra-adaptable nanovesicular systems: a carrier for systemic delivery of therapeutic agents
|
Kumar, Ajay
|
|
2012
|
|
21-22 |
p. 1233-1241
9 p.
|
artikel
|
| 109 |
Unearthing a source of medicinal molecules
|
Cooper, Edwin L.
|
|
2010
|
|
21-22 |
p. 966-972
7 p.
|
artikel
|
| 110 |
Vector-based RNAi approaches for stable, inducible and genome-wide screens
|
Fewell, Gwen D.
|
|
2006
|
|
21-22 |
p. 975-982
8 p.
|
artikel
|
| 111 |
What are the prospects of slowing the progression of Alzheimer's disease?
|
Palmer, Alan M.
|
|
2012
|
|
21-22 |
p. 1157-1159
3 p.
|
artikel
|
| 112 |
What is the most important approach in current drug discovery: doing the right things or doing things right?
|
Elebring, Thomas
|
|
2012
|
|
21-22 |
p. 1166-1169
4 p.
|
artikel
|
| 113 |
What is the value of human FMRI in CNS drug development?
|
Wise, Richard G.
|
|
2010
|
|
21-22 |
p. 973-980
8 p.
|
artikel
|
| 114 |
Where do innovative drugs come from?
|
Higgs, Gerry
|
|
2011
|
|
21-22 |
p. 907-909
3 p.
|
artikel
|
| 115 |
Will biomedical innovation change the future of healthcare?
|
Schmid, Esther F.
|
|
2009
|
|
21-22 |
p. 1037-1044
8 p.
|
artikel
|
Tijdschrift beschrijving